TN SB0733 | 2023-2024 | 113th General Assembly


Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on January 30 2023 - 25% progression
Action: 2023-03-15 - Action deferred in Senate Health and Welfare Committee to 1/24/2024
Pending: Senate Health and Welfare Committee
Text: Latest bill text (Draft #1) [PDF]


As introduced, prohibits a healthcare provider from prescribing a buprenorphine product unless the patient has first signed a copy of an informational document on the risks of buprenorphine use to pregnant women, unborn children, and infants; requires the department of health to make available on its public website the informational document within 90 days of the effective date of the act. - Amends TCA Title 53 and Title 63.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.


AN ACT to amend Tennessee Code Annotated, Title 53 and Title 63, relative to buprenorphine.



2023-03-15SenateAction deferred in Senate Health and Welfare Committee to 1/24/2024
2023-03-08SenatePlaced on Senate Health and Welfare Committee calendar for 3/15/2023
2023-02-06SenatePassed on Second Consideration, refer to Senate Health and Welfare Committee
2023-02-02SenateIntroduced, Passed on First Consideration
2023-01-30SenateFiled for introduction

Same As/Similar To

HB0665 (Crossfiled) 2023-02-01 - Assigned to s/c Health Subcommittee


Tennessee State Sources

Bill Comments